269 related articles for article (PubMed ID: 24655482)
1. Microglial Cx3cr1 knockout reduces prion disease incubation time in mice.
Grizenkova J; Akhtar S; Brandner S; Collinge J; Lloyd SE
BMC Neurosci; 2014 Mar; 15():44. PubMed ID: 24655482
[TBL] [Abstract][Full Text] [Related]
2. Knockout of fractalkine receptor Cx3cr1 does not alter disease or microglial activation in prion-infected mice.
Striebel JF; Race B; Carroll JA; Phillips K; Chesebro B
J Gen Virol; 2016 Jun; 97(6):1481-1487. PubMed ID: 26935332
[TBL] [Abstract][Full Text] [Related]
3. Abnormal activation of microglia accompanied with disrupted CX3CR1/CX3CL1 pathway in the brains of the hamsters infected with scrapie agent 263K.
Xie WL; Shi Q; Zhang J; Zhang BY; Gong HS; Guo Y; Wang SB; Xu Y; Wang K; Chen C; Liu Y; Dong XP
J Mol Neurosci; 2013 Nov; 51(3):919-32. PubMed ID: 23526370
[TBL] [Abstract][Full Text] [Related]
4. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.
Lee S; Varvel NH; Konerth ME; Xu G; Cardona AE; Ransohoff RM; Lamb BT
Am J Pathol; 2010 Nov; 177(5):2549-62. PubMed ID: 20864679
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin S contributes to microglia-mediated olfactory dysfunction through the regulation of Cx3cl1-Cx3cr1 axis in a Niemann-Pick disease type C1 model.
Seo Y; Kim HS; Kang I; Choi SW; Shin TH; Shin JH; Lee BC; Lee JY; Kim JJ; Kook MG; Kang KS
Glia; 2016 Dec; 64(12):2291-2305. PubMed ID: 27687148
[TBL] [Abstract][Full Text] [Related]
6. Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes.
Mecca C; Giambanco I; Donato R; Arcuri C
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361745
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 modulates microglial activity through regulation of chemokine (C-X3-C) receptor 1 -mediated signalling pathways.
Ma B; Xu L; Pan X; Sun L; Ding J; Xie C; Koliatsos VE; Cai H
Hum Mol Genet; 2016 Aug; 25(16):3515-3523. PubMed ID: 27378696
[TBL] [Abstract][Full Text] [Related]
8. CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection.
Chen P; Zhao W; Guo Y; Xu J; Yin M
Biomed Res Int; 2016; 2016():8090918. PubMed ID: 27429982
[TBL] [Abstract][Full Text] [Related]
9. Microglial phagocytosis and activation underlying photoreceptor degeneration is regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa.
Zabel MK; Zhao L; Zhang Y; Gonzalez SR; Ma W; Wang X; Fariss RN; Wong WT
Glia; 2016 Sep; 64(9):1479-91. PubMed ID: 27314452
[TBL] [Abstract][Full Text] [Related]
10. Role of fractalkine/CX3CR1 interaction in light-induced photoreceptor degeneration through regulating retinal microglial activation and migration.
Zhang M; Xu G; Liu W; Ni Y; Zhou W
PLoS One; 2012; 7(4):e35446. PubMed ID: 22536384
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Tat disrupts CX3CL1-CX3CR1 axis in microglia via the NF-κBYY1 pathway.
Duan M; Yao H; Cai Y; Liao K; Seth P; Buch S
Curr HIV Res; 2014; 12(3):189-200. PubMed ID: 24862326
[TBL] [Abstract][Full Text] [Related]
12. Protracted downregulation of CX3CR1 on microglia of aged mice after lipopolysaccharide challenge.
Wynne AM; Henry CJ; Huang Y; Cleland A; Godbout JP
Brain Behav Immun; 2010 Oct; 24(7):1190-201. PubMed ID: 20570721
[TBL] [Abstract][Full Text] [Related]
13. The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.
Pawelec P; Ziemka-Nalecz M; Sypecka J; Zalewska T
Cells; 2020 Oct; 9(10):. PubMed ID: 33065974
[TBL] [Abstract][Full Text] [Related]
14. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
15. Involvement of CX3CL1/CX3CR1 in depression and cognitive impairment induced by chronic unpredictable stress and relevant underlying mechanism.
Liu Y; Zhang T; Meng D; Sun L; Yang G; He Y; Zhang C
Behav Brain Res; 2020 Mar; 381():112371. PubMed ID: 31765724
[TBL] [Abstract][Full Text] [Related]
16. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS.
Hughes PM; Botham MS; Frentzel S; Mir A; Perry VH
Glia; 2002 Mar; 37(4):314-27. PubMed ID: 11870871
[TBL] [Abstract][Full Text] [Related]
17. CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.
Subbarayan MS; Joly-Amado A; Bickford PC; Nash KR
Pharmacol Ther; 2022 Mar; 231():107989. PubMed ID: 34492237
[TBL] [Abstract][Full Text] [Related]
18. CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes.
Liu C; Luo D; Streit WJ; Harrison JK
J Neuroimmunol; 2008 Jul; 198(1-2):98-105. PubMed ID: 18508133
[TBL] [Abstract][Full Text] [Related]
19. Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice.
Staniland AA; Clark AK; Wodarski R; Sasso O; Maione F; D'Acquisto F; Malcangio M
J Neurochem; 2010 Aug; 114(4):1143-57. PubMed ID: 20524966
[TBL] [Abstract][Full Text] [Related]
20. CX3CR1 RNAi inhibits hypoxia-induced microglia activation via p38MAPK/PKC pathway.
Liu Y; Zhao T; Yang Z; Li Q
Int J Exp Pathol; 2014 Apr; 95(2):153-7. PubMed ID: 24628787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
